Work

Data Supplement from Phase I Dose-Escalation Study of MEDI-573, a Bispecific, Antiligand Monoclonal Antibody against IGFI and IGFII, in Patients with Advanced Solid Tumors

Year: 2023

Type: other

Abstract: Figure S1. Top: mRNA differential expression of individual proliferation genes (AURKA, CCNB1, MKI67, and MYBL2) and cancer invasion genes (CTSL2 and MMP11) and the bladder cancer marker, UPK3A, in biopsy samples (from patients with bladder cancer at pretreatment and after treatment at 5 mg/kg and 15 mg/kg. Bottom: Composite differential expression score from pretreatment and post-treatment tissues of proliferation, invasion, and bladder cancer markers in cohorts 5 mg/kg and 15 mg/kg.

DOI: 10.1158/1078-0432.22456008.v1

Authors: Paul Haluska, Michael Menefee, Elizabeth R. Plimack, Jonathan Rosenberg, Donald Northfelt, Theresa LaVallee, Li Shi, Xiang-Qing Yu, Patricia Burke, Jaiqi Huang, Jaye Viner, Jennifer McDevitt, Patricia LoRusso

Language: English

Topic: Growth Hormone and Insulin-like Growth Factors

Subfield: Endocrinology, Diabetes and Metabolism

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361911653

Cites:

Cited by:

Related to: 10